CL2018001345A1 - Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. - Google Patents

Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.

Info

Publication number
CL2018001345A1
CL2018001345A1 CL2018001345A CL2018001345A CL2018001345A1 CL 2018001345 A1 CL2018001345 A1 CL 2018001345A1 CL 2018001345 A CL2018001345 A CL 2018001345A CL 2018001345 A CL2018001345 A CL 2018001345A CL 2018001345 A1 CL2018001345 A1 CL 2018001345A1
Authority
CL
Chile
Prior art keywords
methyl
disease
trihydroxytetrahydro
cyanoacetyl
methylpiperidin
Prior art date
Application number
CL2018001345A
Other languages
English (en)
Inventor
Ryan Hudson
Daniel D Long
Donna A A Wilton
Mandy Loo
Patrick J Brassil
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2018001345A1 publication Critical patent/CL2018001345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Compuestos derivados de (2S,3S,4S,5R,6S)-6-(4-(((2-(4-((((2-(4-(((3R,4R)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7H-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2H-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad Crohn y colitis ulcerosa.
CL2018001345A 2015-11-24 2018-05-18 Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa. CL2018001345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
CL2018001345A1 true CL2018001345A1 (es) 2018-06-22

Family

ID=57518004

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001345A CL2018001345A1 (es) 2015-11-24 2018-05-18 Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.

Country Status (32)

Country Link
US (3) US10435428B2 (es)
EP (1) EP3380486B1 (es)
JP (2) JP6778747B2 (es)
KR (1) KR20180080330A (es)
CN (1) CN108290918B (es)
AU (1) AU2016359494B2 (es)
BR (1) BR112018010650A8 (es)
CA (1) CA3003283A1 (es)
CL (1) CL2018001345A1 (es)
CO (1) CO2018005327A2 (es)
CY (1) CY1122918T1 (es)
DK (1) DK3380486T3 (es)
EA (1) EA035816B1 (es)
ES (1) ES2784523T3 (es)
HR (1) HRP20200561T1 (es)
HU (1) HUE049775T2 (es)
IL (1) IL259076B (es)
LT (1) LT3380486T (es)
ME (1) ME03757B (es)
MX (1) MX2018006282A (es)
MY (1) MY189979A (es)
NZ (1) NZ742574A (es)
PH (1) PH12018501037A1 (es)
PL (1) PL3380486T3 (es)
PT (1) PT3380486T (es)
RS (1) RS60237B1 (es)
SG (1) SG11201803686UA (es)
SI (1) SI3380486T1 (es)
TW (1) TWI703147B (es)
UA (1) UA121270C2 (es)
WO (1) WO2017091544A1 (es)
ZA (1) ZA201802967B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077283A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3371185T (pt) 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
ME03757B (me) 2015-11-24 2021-04-20 Theravance Biopharma R&D Ip Llc Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
WO2018165250A1 (en) * 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
EP3609903A1 (en) * 2017-05-23 2020-02-19 Theravance Biopharma R&D IP, LLC Thiocarbamate prodrugs of tofacitinib
AU2018273866B2 (en) 2017-05-23 2021-09-30 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of Janus kinase inhibitors
BR112019025614A2 (pt) * 2017-06-05 2020-06-16 Flagship Pioneering Innovations V, Inc. Agentes multibióticos e métodos de uso dos mesmos
CR20200334A (es) 2018-01-05 2021-03-09 Cybrexa 1 Inc Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
WO2019182322A1 (ko) * 2018-03-20 2019-09-26 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
WO2019246273A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
WO2020034987A1 (zh) * 2018-08-15 2020-02-20 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
US11555015B2 (en) * 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
AU2019378008A1 (en) * 2018-11-15 2021-06-03 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease
CA3123596A1 (en) 2018-12-19 2020-06-25 Incyte Corporation Jak1 pathway inhibitors for the treatment of gastrointestinal disease
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
JP2022541747A (ja) 2019-07-10 2022-09-27 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
US20210139857A1 (en) * 2019-11-13 2021-05-13 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ｉｐ有限責任公司 腸道選擇性ｊａｋ３抑制劑的投與
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
EP4232146A1 (en) * 2020-10-22 2023-08-30 Biora Therapeutics, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
EP4351584A1 (en) * 2021-06-07 2024-04-17 The Regents of the University of California Compositions and methods for treating celiac disease
WO2023225463A2 (en) * 2022-05-14 2023-11-23 3-D Matrix, Ltd. Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
CN1195755C (zh) 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
BR112012008267B1 (pt) 2009-10-09 2022-10-04 Incyte Holdings Corporation Derivados hidroxila, ceto e glucuronida de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1- il)-3-ciclopentilpropanonitrila
US20110152207A1 (en) 2009-12-23 2011-06-23 Goff Jesse P Use of vitamin d glycosides and sulfates for treatment of disease
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
EP2531508A1 (en) * 2010-02-05 2012-12-12 Pfizer Inc. Pyrrolo [ 2, 3 - d]pyrimidine urea compounds as jak inhibitors
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
US20140357557A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US10172921B2 (en) * 2014-06-24 2019-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor
ME03757B (me) 2015-11-24 2021-04-20 Theravance Biopharma R&D Ip Llc Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti
ES2954596T3 (es) 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
NZ742574A (en) 2018-11-30
SI3380486T1 (sl) 2020-07-31
IL259076B (en) 2021-05-31
PL3380486T3 (pl) 2020-07-27
UA121270C2 (uk) 2020-04-27
ZA201802967B (en) 2019-04-24
PH12018501037A1 (en) 2019-01-28
CN108290918B (zh) 2021-06-08
JP2019501133A (ja) 2019-01-17
US10961267B2 (en) 2021-03-30
AU2016359494A1 (en) 2018-06-14
ES2784523T3 (es) 2020-09-28
MY189979A (en) 2022-03-22
BR112018010650A2 (pt) 2018-11-13
CO2018005327A2 (es) 2018-05-31
AU2016359494B2 (en) 2021-01-07
US10435428B2 (en) 2019-10-08
US20170145044A1 (en) 2017-05-25
WO2017091544A1 (en) 2017-06-01
PT3380486T (pt) 2020-05-22
EA035816B1 (ru) 2020-08-14
IL259076A (en) 2018-06-28
SG11201803686UA (en) 2018-06-28
EA201891248A1 (ru) 2018-10-31
EP3380486B1 (en) 2020-02-19
HRP20200561T1 (hr) 2020-06-26
KR20180080330A (ko) 2018-07-11
EP3380486A1 (en) 2018-10-03
BR112018010650A8 (pt) 2019-02-26
US20190389895A1 (en) 2019-12-26
TW201720827A (zh) 2017-06-16
CY1122918T1 (el) 2021-10-29
CN108290918A (zh) 2018-07-17
JP2020196742A (ja) 2020-12-10
RS60237B1 (sr) 2020-06-30
ME03757B (me) 2021-04-20
LT3380486T (lt) 2020-05-11
JP6778747B2 (ja) 2020-11-04
HUE049775T2 (hu) 2020-10-28
TWI703147B (zh) 2020-09-01
DK3380486T3 (da) 2020-05-18
CA3003283A1 (en) 2017-06-01
US11608354B2 (en) 2023-03-21
US20210179655A1 (en) 2021-06-17
MX2018006282A (es) 2019-01-21

Similar Documents

Publication Publication Date Title
CL2018001345A1 (es) Compuestos derivados de (2s,3s,4s,5r,6s)-6-(4-(((2-(4-((((2-(4-(((3r,4r)-1-(2-cianoacetil)-4-metilpiperidin-3-il)(metil)(amino)-7h-pirrol-[2,3-d]-pirimidin-7-carboxamido)-etil)-carbamoil)-oxi)-metil)-fenoxi)-3,4,5-trihidroxitetrahidro-2h-piran-2-carboxílico; procedimiento de preparación; composición farmacéutica; útiles para el tratamiento de una enfermedad inflamatoria gastrointestinal, tal como enfermedad crohn y colitis ulcerosa.
PH12020500529A1 (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
WO2015132799A3 (en) Heterocyclic compounds
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
EP3828186A3 (en) Pyrimidinones as factor xia inhibitors
PH12018500653A1 (en) Salts and solid forms of monobactam antibiotic
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
IN2014KN00948A (es)
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
HK1243424A1 (zh) 4'-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
HK1257615A1 (zh) 用於治療癌症、含有多酚化合物作為活性成分的藥物組合物
WO2013109972A3 (en) Therapeutic compounds
ZA201605379B (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
IT1399223B1 (it) Apparato per lavorare cornici di infissi.
EA201691741A1 (ru) Фармацевтическая композиция
WO2015001541A3 (en) Pharmaceutical film composition
MA42264A (fr) Procédé de préparation d'oltipraz
EP3542797A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DYRK-RELATED ILLNESSES USING PYRIDINE-BASED COMPOUNDS AS AN ACTIVE SUBSTANCE
EP3424500A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRROLO-CONDENSUS, 6-LOW HETEROCYCLIC COMPOUND
HK1216253A1 (zh) 新型化合物、其藥學上可接受的鹽或光學異構體、用於製備它們的方法以及包含它們作為有效成分的用於預防或治療病毒性疾病的藥物組合物
EP3114112A4 (en) Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol
PE20170522A1 (es) Forma polimorfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi) bencilamina para el tratamiento del alzheimer